Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 04, 2026 08:00 ET | Source: Beyond Air™

Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026

GARDEN CITY, N.Y., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for...
January 27, 2026 16:05 ET | Source: Beyond Air™

Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences

GARDEN CITY, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...
January 26, 2026 16:05 ET | Source: Beyond Air™

Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...
January 14, 2026 08:30 ET | Source: Beyond Air™

Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

GARDEN CITY, N.Y., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...
January 13, 2026 07:30 ET | Source: Beyond Air™

XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved...